FDA Approves New Warnings for Kybella Injections Due to Adverse Reactions from Unapproved Use
The U.S. Food and Drug Administration (FDA) has approved significant updates to the labeling for Kybella (deoxycholic acid) injection. These updates include new warnings regarding adverse reactions that can occur when the drug is used outside its approved indication, which is for submental fat (under the chin). The FDA now explicitly recommends against this unapproved use. This decision follows a comprehensive review of reports from the FDA Adverse Event Reporting System (FAERS) and medical literature, which revealed that administering Kybella outside the submental fat region can lead to serious neuromuscular and other adverse events. Additionally, the FDA has added language to the Warnings and Precautions section concerning the serious risks of injection site nodules (3 cm or smaller) and masses (larger than 3 cm). These nodules and masses may not resolve over time and could require medical intervention, occurring even when Kybella is used as indicated in the submental area, as well as in unapproved areas...
